PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 38/27, C12N 5/06

A2

(11) International Publication Number: WO 00/30675

(43) International Publication Date: 2 June 2000 (02.06.00)

(21) International Application Number: PCT/SE99/02197

(22) International Filing Date: 25 November 1999 (25.11.99)

(30) Priority Data:
9804064-5 25 November 1998 (25.11.98) SE

(71) Applicant *(for all designated States except US)*: A+ SCIENCE INVEST AB [SE/SE]; P.O. Box 3096, S-400 10 Göteborg (SE).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: ERIKSSON, Peter [SE/SE]; Dr. Saléns Gata 10, S-413 22 Göteborg (SE).

(74) Agent: AWAPATENT AB; P.O. Box 11394, S-404 28 Göteborg (SE).

(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: MEDICINAL PRODUCT AND METHOD FOR TREATMENT OF CONDITIONS AFFECTING NEURAL STEM CELLS OR PROGENITOR CELLS

(57) Abstract

Use of a substance that upon administration will lead to increased concentrations of growth hormone, such as growth hormone, a functionally equivalent analogue thereof or a substance that will increase the release of endogenous growth hormone, for the production of a medicinal product for treatment of abnormal conditions affecting neural stem cells, progenitor cells and/or cells derived from neural stem cells or progenitor cells, especially conditions affecting the oligodendroglia, astroglia, and/or neuronal cells. In vitro and in vivo methods for inducing lineage determination, propagating and/or inducing or maintaining the genesis of neurons, oligodendrocytes, astroglial cells from progenitor cells, stem cells and/or cells derived from said cells by administrating to the cells a substance that increases the concentration of growth hormone. Also a method of reducing the genesis of oligodendrocytes, neurons, astroglial cells from progenitor cells or stem cells, wherein a pharmaceutically effective amount of a substance that will lead to a decreased concentration of growth hormone or a functionally equivalent analogue thereof is administered to said patient.